Latin America Blastic Plasmacytoid Dendritic Cell Neoplasm Market Size & Outlook
The blastic plasmacytoid dendritic cell neoplasm market in Latin America is expected to reach a projected revenue of US$ 7.5 million by 2030. A compound annual growth rate of 6.5% is expected of Latin America blastic plasmacytoid dendritic cell neoplasm market from 2024 to 2030.
Revenue, 2023 (US$M)
$4.8
Forecast, 2030 (US$M)
$7.5
CAGR, 2024 - 2030
6.5%
Report Coverage
Latin America
Related Markets
Latin America blastic plasmacytoid dendritic cell neoplasm market highlights
- The Latin America blastic plasmacytoid dendritic cell neoplasm market generated a revenue of USD 4.8 million in 2023.
- The market is expected to grow at a CAGR of 6.5% from 2024 to 2030.
- In terms of segment, chemotherapy was the largest revenue generating treatment in 2023.
- Chemotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Latin America data book summary
| Market revenue in 2023 | USD 4.8 million |
| Market revenue in 2030 | USD 7.5 million |
| Growth rate | 6.5% (CAGR from 2024 to 2030) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Chemotherapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy |
| Key market players worldwide | AbbVie Inc, ImmunoGen, Genentech, Jazz Pharmaceuticals PLC, Resverlogix Corp |
Other key industry trends
- In terms of revenue, Latin America region accounted for 3.7% of the global blastic plasmacytoid dendritic cell neoplasm market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 52.9 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Blastic Plasmacytoid Dendritic Cell Neoplasm Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Xencor | View profile | 251-500 | Monrovia, California, United States, North America | http://xencor.com |
| Cellex | View profile | 251-500 | Köln, Nordrhein-Westfalen, Germany, Europe | https://www.cellex.me/en |
| Stemline Therapeutics | View profile | 11-50 | New York, New York, United States, North America | http://www.stemline.com |
| ImmunoGen | View profile | 501-1000 | Waltham, Massachusetts, United States, North America | http://www.immunogen.com |
| Jazz Pharmaceuticals PLC | View profile | 2800 | Waterloo Road, Fifth Floor, Waterloo Exchange, Dublin, Ireland, D04 E5W7 | https://www.jazzpharmaceuticals.com |
| Genentech | View profile | 10001+ | South San Francisco, California, United States, North America | http://gene.com |
| Resverlogix Corp | View profile | 18 | 4820 Richard Road South West, Suite 300, Calgary, AB, Canada, T3E 6L1 | https://www.resverlogix.com |
| AbbVie Inc | View profile | 50000 | 1 North Waukegan Road, North Chicago, IL, United States, 60064-6400 | http://www.abbvieinvestor.com |
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
